Prevalence of Impurity Retention Mechanisms in Pharmaceutical Crystallizations

被引:27
作者
Nordstrom, Fredrik L. [3 ]
Sirota, Eric [1 ]
Hartmanshenn, Clara [1 ]
Kwok, Thomas T. [1 ]
Paolello, Mitchell [2 ]
Li, Huayu [3 ]
Abeyta, Vincent [3 ]
Bramante, Tommasina [3 ]
Madrigal, Emma [1 ]
Behre, Taylor [1 ]
Capellades, Gerard [2 ]
机构
[1] Merck & Co Inc, Proc Res & Dev, Rahway, NJ 07065 USA
[2] Rowan Univ, Dept Chem Engn, Glassboro, NJ 08028 USA
[3] Boehringer Ingelheim GmbH & Co KG, Mat & Analyt Sci, Ridgefield, CT 06877 USA
关键词
crystallization; impurities; pharmaceuticals; solid solutions; purification; precipitation; MIXED-PRODUCT REMOVAL; CONTINUOUS FILTRATION; SOLUBILITY; GROWTH; PURITY; SUSPENSION; CRYSTALS; KINETICS; MODEL;
D O I
10.1021/acs.oprd.3c00009
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
The rejection of process impurities from crystallizing products is an essential step for the purification of pharmaceutical drugs and for the isolation of active pharmaceutical ingredients with the right crystal quality attributes. While several impurity incorporation mechanisms have been reported in the literature, the frequency of those mechanisms in actual industrial processes is largely unknown. This work presents the outcome of a joint investigation by crystallization scientists from two pharmaceutical companies and an academic institution, on the prevalence of impurity retention mechanisms in cooling and antisolvent crystallizations. A total of 52 product-impurity pairs have been explored in detail using the so-called Solubility-Limited Impurity Purge (SLIP) test as the diagnostic tool to identify the underlying impurity retention mechanism of already crystallized materials with challenging impurities. The results show that formation of solid solutions is the most common mechanism, where the impurity and product are partially miscible in the solid state. In 73% of cases, only one solid solution phase was obtained in which the impurity became incorporated into the crystal lattice of the product (alpha phase). In 6% of the examples, two solid solution phases were obtained, where the second solid phase (beta phase) comprised predominantly the impurity and the product was the minor component. The remaining impurity retention mechanisms (21%) are related to solid-state immiscible impurities that precipitated from solution resulting in a physical mixture between the product and the impurity. The reasons for the results are discussed through a comprehensive analysis of theoretical reported retention mechanisms, which includes physical constraints for the scale-up of isolation processes, thermodynamic assessments using ternary phase diagrams, and restrictions in the context of current pharmaceutical syntheses of small organic molecules. Three industrial case studies are presented that exemplify how knowledge of the retention mechanisms can be used to delineate appropriate strategies for process design and to effectively purge these impurities during crystallization or washing.
引用
收藏
页码:723 / 741
页数:19
相关论文
共 56 条
[1]   Evaluation of mixed suspension mixed product removal crystallization processes coupled with a continuous filtration system [J].
Acevedo, David ;
Pena, Ramon ;
Yang, Yang ;
Barton, Alastair ;
Firth, Paul ;
Nagy, Zoltan K. .
CHEMICAL ENGINEERING AND PROCESSING-PROCESS INTENSIFICATION, 2016, 108 :212-219
[2]   Increased chemical purity using a hydrate [J].
Black, SN ;
Cuthbert, MW ;
Roberts, RJ ;
Stensland, B .
CRYSTAL GROWTH & DESIGN, 2004, 4 (03) :539-544
[3]   Why Do Some Molecules Form Hydrates or Solvates? [J].
Boothroyd, Simon ;
Kerridge, Andy ;
Broo, Anders ;
Buttar, David ;
Anwar, Jamshed .
CRYSTAL GROWTH & DESIGN, 2018, 18 (03) :1903-1908
[4]   Multi-Impurity Adsorption Model for Modeling Crystal Purity and Shape Evolution during Crystallization Processes in Impure Media [J].
Borsos, Akos ;
Majumder, Aniruddha ;
Nagy, Zoltan K. .
CRYSTAL GROWTH & DESIGN, 2016, 16 (02) :555-568
[5]   Impurity incorporation in solution crystallization: diagnosis, prevention, and control [J].
Capellades, Gerard ;
Bonsu, Jacob O. ;
Myerson, Allan S. .
CRYSTENGCOMM, 2022, 24 (11) :1989-2001
[6]   On-Demand Continuous Manufacturing of Ciprofloxacin in Portable Plug-and-Play Factories: Implementation and In Situ Control of Downstream Production [J].
Capellades, Gerard ;
Neurohr, Clemence ;
Briggs, Naomi ;
Rapp, Kersten ;
Hammersmith, Gregory ;
Brancazio, David ;
Derksen, Bridget ;
Myerson, Allan S. .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2021, 25 (07) :1534-1546
[7]   A Compact Device for the Integrated Filtration, Drying, and Mechanical Processing of Active Pharmaceutical Ingredients [J].
Capellades, Gerard ;
Neurohr, Clemence ;
Azad, Mohammad ;
Brancazio, David ;
Rapp, Kersten ;
Hammersmith, Gregory ;
Myerson, Allan S. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 109 (03) :1365-1372
[8]   Mixed-Suspension, Mixed-Product Removal Studies of Ciprofloxacin from Pure and Crude Active Pharmaceutical Ingredients: The Role of Impurities on Solubility and Kinetics [J].
Capellades, Gerard ;
Wiemeyer, Helena ;
Myerson, Allan S. .
CRYSTAL GROWTH & DESIGN, 2019, 19 (07) :4008-4018
[9]   Quantitative Impurity Rejection Analysis for Crystallization [J].
Caspi, Daniel D. ;
Nordstrom, Fredrik L. .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2018, 22 (07) :856-861
[10]   Kilogram-scale prexasertib monolactate monohydrate synthesis under continuous-flow CGMP conditions [J].
Cole, Kevin P. ;
Groh, Jennifer McClary ;
Johnson, Martin D. ;
Burcham, Christopher L. ;
Campbell, Bradley M. ;
Diseroad, William D. ;
Heller, Michael R. ;
Howell, John R. ;
Kallman, Neil J. ;
Koenig, Thomas M. ;
May, Scott A. ;
Miller, Richard D. ;
Mitchell, David ;
Myers, David P. ;
Myers, Steven S. ;
Phillips, Joseph L. ;
Polster, Christopher S. ;
White, Timothy D. ;
Cashman, Jim ;
Hurley, Declan ;
Moylan, Robert ;
Sheehan, Paul ;
Spencer, Richard D. ;
Desmond, Kenneth ;
Desmond, Paul ;
Gowran, Olivia .
SCIENCE, 2017, 356 (6343) :1144-1150